Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.
Santoni M, Aurilio G, Massari F, Grande E, Matrana MR, Rizzo M, De Giorgi U, Incorvaia L, Martignetti A, Molina-Cerrillo J, Zabalza IO, Mollica V, Rizzo A, Battelli N, Porta C.
Santoni M, et al. Among authors: rizzo m, rizzo a.
Clin Genitourin Cancer. 2022 Jun;20(3):285-295. doi: 10.1016/j.clgc.2022.02.003. Epub 2022 Feb 19.
Clin Genitourin Cancer. 2022.
PMID: 35305916